Positive PhIII results in hand, Concert Pharma forges ahead with NDA and commercialization plans for hair loss drug
Concert Pharmaceuticals has been waiting to tout Phase III data amidst a sell-off of the bulk of its pipeline to Terran Biosciences and several other events for the biotech. And on Monday, the company rolled out the red carpet.
Concert unveiled topline results from its second Phase III clinical trial, dubbed THRIVE-AA2, evaluating its oral candidate currently called CTP-543 in adult patients with moderate to severe alopecia areata. The candidate is an inhibitor of Janus kinases JAK1 and JAK2.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.